For example, BRCA1 and BRCA2 mutations and PARP inhibitors are synthetically lethal, which has become the conceptual basis for the new therapeutic paradigm of PARP inhibition for cancer patients carrying BRCA1 and BRCA2 mutations [75]. Here, BRCA1 is linked to cancer.